Independent consulting services in oncology early drug development.
Collective experience managing over 60 Phase I-II oncology clinical trials.
A boutique CRO focused solely on oncology and onco-hematology.
Specialized in early development of single agent and combination anticancer regimens.
MISSIONS
GOALS
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. Vázquez et al. Oncotarget. 2017;31;8(5):7598-613
100 rue Martre
92110 Clichy - FRANCE
Tel: +33 1 47 15 01 01
Fax: +33 1 45 19 06 59